<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608100</url>
  </required_header>
  <id_info>
    <org_study_id>7B5-02-10A01-03</org_study_id>
    <nct_id>NCT01608100</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Cardiac Biomarker Assay</brief_title>
  <official_title>Design Validation Protocol for the Evaluation of ARCHITECT STAT High Sensitive Troponin I Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Diagnostics Division</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Diagnostics Division</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the performance and intended use of a new cardiac
      biomarker test, Troponin I, in an intended use population. Blood specimens will be tested
      using the new investigational test that detects the level of Troponin I. Results will be
      compared to the diagnosis of whether or not an acute myocardial infarction (MI) occurred.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the cardiac biomarker Troponin I is to aid in the diagnosis of myocardial
      infarction.The assay is also intended to assist in the prognosis relative risk to all cause
      mortality (ACM) and major adverse cardiac events (MACE) consisting of myocardial infarction,
      revascularization, and cardiac death in patients who present with symptoms suggestive of
      acute coronary syndrome (ACS) without a diagnosis of myocardial infarction.

      All specimens were collected under a separate specimen collection protocol (Protocol No,
      7B5-02-09A01-01: Clinical Specimen Procurement for Biomarker Evaluation of Suspected ACS).
      The specimens that will be tested include approximately 8300 specimens collected from 1101
      subjects presenting to Emergency Departments with signs and symptoms of Acute Coronary
      Syndrome and will be provided to the clinical sites performing investigational Troponin I
      testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Performance - Area Under the Curve</measure>
    <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department</time_frame>
    <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Area Under the Curve (AUC). The Area Under the Curve that was assessed, is used to determine the optimum clinical sensitivity and specificity for the ARCHITECT STAT High Sensitive Troponin-I assay. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Performance- Sensitivity</measure>
    <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department</time_frame>
    <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Sensitivity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Performance- Specificity</measure>
    <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
    <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Specificity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Performance- Negative Predictive Value (NPV)</measure>
    <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
    <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Negative Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Performance- Positive Predictive Value (PPV)</measure>
    <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
    <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Positive Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognosis</measure>
    <time_frame>30-day and 90-day follow-up</time_frame>
    <description>Specimens were collected at 11 EDs from 1,101 subjects presenting to the ED with symptoms consistent with ACS. All subject diagnoses were adjudicated by three board certified cardiologists according to current standard of care. ARCHITECT STAT High Sensitive Troponin I results were generated from subject specimens and evaluated for use as an aid in the assessment of prognosis. Analyses used the first available troponin result from multiple serial draw time points. Subjects were assessed for risk of all cause mortality (ACM) and major adverse cardiac event (MACE) at 30 day and 90 day time points after ED discharge. MACE consisted of myocardial infarction, urgent revascularization, and cardiac death. Subjects were followed-up for subsequent events by medical record review and/or subject/caregiver contact. Any ACM and MACE that occurred during the ED visit and on the same day as ED discharge were not included in the analyses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1101</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ARCHITECT STAT High Sensitive Troponin I Assay testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ARCHITECT STAT High Sensitive Troponin I Assay</intervention_name>
    <description>Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.
Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.</description>
    <arm_group_label>ARCHITECT STAT High Sensitive Troponin I Assay testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presenting to the Emergency Department with symptoms consistent with or suggestive of
             Acute Coronary Syndrome (ACS) defined as at least 5 minutes of chest pain (or symptoms
             consistent with myocardial ischemia) up to 6 hours prior to initial evaluation.

          -  an Electrocardiogram (ECG) result within 2 hours of presentation for observation of
             Acute Coronary Syndrome (ACS).

          -  greater than 18 years of age.

          -  not known to be pregnant.

          -  agreement to the follow-up required by the study.

        Exclusion Criteria:

          -  prior participation in this study.

          -  require dialysis for end stage renal disease.

          -  history of a previous heart transplant.

          -  coexisting disorder associated with limited life expectancy.

          -  currently participating in another investigational device or drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred S Apple, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minneapolis Medical Research Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Peacock, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Chandler Regional Medical Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Emergency Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Laboratory Services</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John T Mather Memorial Hospital</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University- Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Physicians in Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Physicians in Clinical Research</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Emergency Medicine University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-2877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Hospital</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2012</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ARCHITECT STAT High Sensitive Troponin I Assay Testing</title>
          <description>All subjects will have their blood tested by the investigational Troponin I assay.
ARCHITECT STAT High Sensitive Troponin I Assay: Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay.
Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the time frames (30 days and 90 days) after the Emergency Department visit.
Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ARCHITECT STAT High Sensitive Troponin I Assay Testing</title>
          <description>All subjects will have their blood tested by the investigational ARCHITECT STAT High Sensitive Troponin I assay. Specimens were collected at 11 emergency departments from 1,101 subjects presenting to the emergency department with symptoms consistent with acute coronary syndrome (ACS). All subject diagnoses were adjudicated by three board certified cardiologists according to current standard of care.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Observed Myocardial Infarction Prevalence</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Number Participants with Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number Participants without Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Performance - Area Under the Curve</title>
        <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Area Under the Curve (AUC). The Area Under the Curve that was assessed, is used to determine the optimum clinical sensitivity and specificity for the ARCHITECT STAT High Sensitive Troponin-I assay. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
        <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department</time_frame>
        <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Area Under the Curve in K2 EDTA</title>
            <description>Area Under the Curve for the ARCHITECT High Sensitive Troponin I was evaluated using K2 EDTA tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
          <group group_id="O2">
            <title>Area Under the Curve in Lithium Heparin Separator</title>
            <description>Area Under the Curve for the ARCHITECT High Sensitive Troponin I was evaluated using Lithium Heparin tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
          <group group_id="O3">
            <title>Area Under the Curve in Serum Separator</title>
            <description>Area Under the Curve for the ARCHITECT High Sensitive Troponin I was evaluated using Serum tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Performance - Area Under the Curve</title>
          <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Area Under the Curve (AUC). The Area Under the Curve that was assessed, is used to determine the optimum clinical sensitivity and specificity for the ARCHITECT STAT High Sensitive Troponin-I assay. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
          <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
          <units>Probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1088"/>
                <count group_id="O3" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Area Under the Curve: 0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9326" lower_limit="0.9048" upper_limit="0.9604"/>
                    <measurement group_id="O2" value="0.9197" lower_limit="0.8914" upper_limit="0.9480"/>
                    <measurement group_id="O3" value="0.9412" lower_limit="0.9102" upper_limit="0.9722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Area Under the Curve: 2-4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9431" lower_limit="0.9081" upper_limit="0.9782"/>
                    <measurement group_id="O2" value="0.9349" lower_limit="0.8986" upper_limit="0.9712"/>
                    <measurement group_id="O3" value="0.9419" lower_limit="0.9041" upper_limit="0.9796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Area Under the Curve: 4-9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9503" lower_limit="0.9419" upper_limit="0.9857"/>
                    <measurement group_id="O2" value="0.9498" lower_limit="0.9190" upper_limit="0.9805"/>
                    <measurement group_id="O3" value="0.9449" lower_limit="0.9046" upper_limit="0.9852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9326</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9048</ci_lower_limit>
            <ci_upper_limit>0.9604</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9431</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9081</ci_lower_limit>
            <ci_upper_limit>0.9782</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9503</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9419</ci_lower_limit>
            <ci_upper_limit>0.9857</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9197</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8914</ci_lower_limit>
            <ci_upper_limit>0.9480</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9349</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8986</ci_lower_limit>
            <ci_upper_limit>0.9712</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9498</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9190</ci_lower_limit>
            <ci_upper_limit>0.9805</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9412</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9102</ci_lower_limit>
            <ci_upper_limit>0.9722</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9419</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9041</ci_lower_limit>
            <ci_upper_limit>0.9796</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Area Under the Curve</param_type>
            <param_value>0.9449</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9046</ci_lower_limit>
            <ci_upper_limit>0.9852</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prognosis</title>
        <description>Specimens were collected at 11 EDs from 1,101 subjects presenting to the ED with symptoms consistent with ACS. All subject diagnoses were adjudicated by three board certified cardiologists according to current standard of care. ARCHITECT STAT High Sensitive Troponin I results were generated from subject specimens and evaluated for use as an aid in the assessment of prognosis. Analyses used the first available troponin result from multiple serial draw time points. Subjects were assessed for risk of all cause mortality (ACM) and major adverse cardiac event (MACE) at 30 day and 90 day time points after ED discharge. MACE consisted of myocardial infarction, urgent revascularization, and cardiac death. Subjects were followed-up for subsequent events by medical record review and/or subject/caregiver contact. Any ACM and MACE that occurred during the ED visit and on the same day as ED discharge were not included in the analyses.</description>
        <time_frame>30-day and 90-day follow-up</time_frame>
        <population>30 Day and 90-day prognosis (Kaplan Meier analysis) and Hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) are summarized. *Censored is defined as the subject has not experienced ACM/MACE at the indicated follow-up time point.</population>
        <group_list>
          <group group_id="O1">
            <title>30-day Prognosis for K2 EDTA Tube Type</title>
            <description>The 30-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
          <group group_id="O2">
            <title>90-day Prognosis for K2 EDTA Tube Type</title>
            <description>The 90-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
          <group group_id="O3">
            <title>30-day Prognosis for Lithium Heparin Separator Tube Type</title>
            <description>The 30-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
          <group group_id="O4">
            <title>90-day Prognosis for Lithium Heparin Separator Tube Type</title>
            <description>The 90-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
          <group group_id="O5">
            <title>30-day Prognosis for Serum Separator Tube Type</title>
            <description>The 30-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
          <group group_id="O6">
            <title>90-day Prognosis for Serum Separator Tube Type</title>
            <description>The 90-day prognosis (Kaplan-Meier analysis) and hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) were calculated.</description>
          </group>
        </group_list>
        <measure>
          <title>Prognosis</title>
          <description>Specimens were collected at 11 EDs from 1,101 subjects presenting to the ED with symptoms consistent with ACS. All subject diagnoses were adjudicated by three board certified cardiologists according to current standard of care. ARCHITECT STAT High Sensitive Troponin I results were generated from subject specimens and evaluated for use as an aid in the assessment of prognosis. Analyses used the first available troponin result from multiple serial draw time points. Subjects were assessed for risk of all cause mortality (ACM) and major adverse cardiac event (MACE) at 30 day and 90 day time points after ED discharge. MACE consisted of myocardial infarction, urgent revascularization, and cardiac death. Subjects were followed-up for subsequent events by medical record review and/or subject/caregiver contact. Any ACM and MACE that occurred during the ED visit and on the same day as ED discharge were not included in the analyses.</description>
          <population>30 Day and 90-day prognosis (Kaplan Meier analysis) and Hazard ratios (Cox regression) for the overall 99th percentile cutoff (26.2 pg/mL) are summarized. *Censored is defined as the subject has not experienced ACM/MACE at the indicated follow-up time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1064"/>
                <count group_id="O2" value="1064"/>
                <count group_id="O3" value="1085"/>
                <count group_id="O4" value="1085"/>
                <count group_id="O5" value="1027"/>
                <count group_id="O6" value="1027"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE/ACM with Troponin value &lt;/= cutoff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No MACE/ACM (*Censored) with TnI value &lt;/= cutoff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="802"/>
                    <measurement group_id="O2" value="791"/>
                    <measurement group_id="O3" value="803"/>
                    <measurement group_id="O4" value="790"/>
                    <measurement group_id="O5" value="796"/>
                    <measurement group_id="O6" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE/ACM with Troponin value &gt; cutoff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No MACE/ACM (*Censored) with TnI value &gt; cutoff</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="212"/>
                    <measurement group_id="O3" value="246"/>
                    <measurement group_id="O4" value="231"/>
                    <measurement group_id="O5" value="201"/>
                    <measurement group_id="O6" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>7.00</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>2.31</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.59</ci_lower_limit>
            <ci_upper_limit>5.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>12.76</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>3.65</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.21</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>7.17</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>2.07</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.84</ci_lower_limit>
            <ci_upper_limit>6.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>12.83</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>3.66</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.25</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>6.07</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>2.09</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>6.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>12.15</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value greater than the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Kaplan-Meier</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Proportion Percentage</param_type>
            <param_value>3.57</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Proportion percentage for subjects with ARCHITECT Troponin value less than or equal to the cutoff</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Likelihood Ratio</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>6.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Performance- Sensitivity</title>
        <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Sensitivity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
        <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department</time_frame>
        <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensitivity in K2 EDTA</title>
            <description>Sensitivity for the ARCHITECT High Sensitive Troponin I was evaluated using K2 EDTA tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
          <group group_id="O2">
            <title>Sensitivity in Lithium Heparin Separator</title>
            <description>Sensitivity for the ARCHITECT High Sensitive Troponin I was evaluated using Lithium Heparin tube type for 3 collection time points. The results were calculated using the overall (99th percentile cutoff 26.2 pg/mL).</description>
          </group>
          <group group_id="O3">
            <title>Sensitivity in Serum Separator</title>
            <description>Sensitivity for the ARCHITECT High Sensitive Troponin I was evaluated using Serum tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Performance- Sensitivity</title>
          <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Sensitivity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
          <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
          <units>percentage MI withTnI &gt;cutoff vs all MI</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1088"/>
                <count group_id="O3" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Sensitivity: 0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.44" lower_limit="75.28" upper_limit="91.23"/>
                    <measurement group_id="O2" value="85.26" lower_limit="76.51" upper_limit="91.70"/>
                    <measurement group_id="O3" value="87.32" lower_limit="77.30" upper_limit="94.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Sensitivity: 2-4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.21" lower_limit="83.81" upper_limit="97.09"/>
                    <measurement group_id="O2" value="91.86" lower_limit="83.95" upper_limit="96.66"/>
                    <measurement group_id="O3" value="92.00" lower_limit="83.40" upper_limit="97.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Sensitivity: 4-9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.90" lower_limit="86.34" upper_limit="97.99"/>
                    <measurement group_id="O2" value="94.95" lower_limit="88.61" upper_limit="98.34"/>
                    <measurement group_id="O3" value="93.15" lower_limit="84.74" upper_limit="97.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>84.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75.28</ci_lower_limit>
            <ci_upper_limit>91.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>92.21</param_value>
            <ci_percent>83.81</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.81</ci_lower_limit>
            <ci_upper_limit>97.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>93.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.34</ci_lower_limit>
            <ci_upper_limit>97.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>85.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.51</ci_lower_limit>
            <ci_upper_limit>91.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>91.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.95</ci_lower_limit>
            <ci_upper_limit>96.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>94.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.61</ci_lower_limit>
            <ci_upper_limit>98.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>87.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.30</ci_lower_limit>
            <ci_upper_limit>94.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>92.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.40</ci_lower_limit>
            <ci_upper_limit>97.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Sensitivity</param_type>
            <param_value>93.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.74</ci_lower_limit>
            <ci_upper_limit>97.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Performance- Specificity</title>
        <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Specificity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
        <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
        <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Specificity in K2 EDTA</title>
            <description>Specificity for the ARCHITECT High Sensitive Troponin I was evaluated using K2 EDTA tube type for 3 collection time points. The results were calculated using the overall (99th percentile cutoff 26.2 pg/mL).</description>
          </group>
          <group group_id="O2">
            <title>Specificity in Lithium Heparin Separator</title>
            <description>Specificity for the ARCHITECT High Sensitive Troponin I was evaluated using Lithium Heparin tube type for 3 collection time points. The results were calculated using the overall (99th percentile cutoff 26.2 pg/mL).</description>
          </group>
          <group group_id="O3">
            <title>Specificity in Serum Separator</title>
            <description>Specificity for the ARCHITECT High Sensitive Troponin I was evaluated using Serum tube type for 3 collection time points. The results were calculated using the overall (99th percentile cutoff 26.2 pg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Performance- Specificity</title>
          <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Specificity. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
          <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
          <units>% nonMI with TnI &lt;/= cutoff vs all nonMI</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1088"/>
                <count group_id="O3" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% Specificity: 0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.73" lower_limit="83.18" upper_limit="88.03"/>
                    <measurement group_id="O2" value="83.76" lower_limit="81.12" upper_limit="86.17"/>
                    <measurement group_id="O3" value="86.35" lower_limit="83.79" upper_limit="88.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Specificity: 2-4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.20" lower_limit="82.66" upper_limit="87.50"/>
                    <measurement group_id="O2" value="83.72" lower_limit="81.09" upper_limit="86.11"/>
                    <measurement group_id="O3" value="85.81" lower_limit="83.31" upper_limit="88.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% Specificity: 4-9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.82" lower_limit="79.99" upper_limit="85.40"/>
                    <measurement group_id="O2" value="80.72" lower_limit="77.82" upper_limit="83.39"/>
                    <measurement group_id="O3" value="84.05" lower_limit="81.31" upper_limit="86.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>85.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.18</ci_lower_limit>
            <ci_upper_limit>88.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>85.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.66</ci_lower_limit>
            <ci_upper_limit>87.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>82.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.99</ci_lower_limit>
            <ci_upper_limit>85.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>83.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.12</ci_lower_limit>
            <ci_upper_limit>86.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>83.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.09</ci_lower_limit>
            <ci_upper_limit>86.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>80.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.82</ci_lower_limit>
            <ci_upper_limit>83.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>86.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.79</ci_lower_limit>
            <ci_upper_limit>88.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>85.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.31</ci_lower_limit>
            <ci_upper_limit>88.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Specificity</param_type>
            <param_value>84.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.31</ci_lower_limit>
            <ci_upper_limit>86.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Performance- Negative Predictive Value (NPV)</title>
        <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Negative Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
        <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
        <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Negative Predictive Value in K2 EDTA</title>
            <description>Negative Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using K2 EDTA tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff 26.2 pg/mL).</description>
          </group>
          <group group_id="O2">
            <title>Negative Predictive Value in Lithium Heparin Separator</title>
            <description>Negative Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using Lithium Heparin tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff 26.2 pg/mL).</description>
          </group>
          <group group_id="O3">
            <title>Negative Predictive Value in Serum Separator</title>
            <description>Negative Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using Serum tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff 26.2 pg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Performance- Negative Predictive Value (NPV)</title>
          <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating Negative Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
          <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
          <units>%nonMI,TnI&lt;/=cutoff vs all TnI&lt;/=cutoff</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1088"/>
                <count group_id="O3" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% NPV: 0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.10" lower_limit="96.82" upper_limit="98.95"/>
                    <measurement group_id="O2" value="98.08" lower_limit="96.81" upper_limit="98.95"/>
                    <measurement group_id="O3" value="98.73" lower_limit="97.61" upper_limit="99.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% NPV: 2-4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.19" lower_limit="98.25" upper_limit="99.70"/>
                    <measurement group_id="O2" value="99.05" lower_limit="98.05" upper_limit="99.62"/>
                    <measurement group_id="O3" value="99.20" lower_limit="98.27" upper_limit="99.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% NPV: 4-9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.23" lower_limit="98.22" upper_limit="99.75"/>
                    <measurement group_id="O2" value="99.24" lower_limit="98.22" upper_limit="99.75"/>
                    <measurement group_id="O3" value="99.25" lower_limit="98.26" upper_limit="99.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>98.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.82</ci_lower_limit>
            <ci_upper_limit>98.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.25</ci_lower_limit>
            <ci_upper_limit>99.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.22</ci_lower_limit>
            <ci_upper_limit>99.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>98.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.81</ci_lower_limit>
            <ci_upper_limit>98.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.05</ci_lower_limit>
            <ci_upper_limit>99.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.22</ci_lower_limit>
            <ci_upper_limit>99.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>98.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.61</ci_lower_limit>
            <ci_upper_limit>99.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.27</ci_lower_limit>
            <ci_upper_limit>99.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Negative Predictive Value</param_type>
            <param_value>99.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.26</ci_lower_limit>
            <ci_upper_limit>99.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Performance- Positive Predictive Value (PPV)</title>
        <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Positive Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
        <time_frame>Troponin value from three collection time points (0-2 hours, &gt;2 and up to 4 hours, &gt;4 hours and up to 9 hours) from subject presentation to the emergency department.</time_frame>
        <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Predictive Value in K2 EDTA</title>
            <description>Positive Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using K2 EDTA tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
          <group group_id="O2">
            <title>Positive Predictive Value in Lithium Heparin Separator</title>
            <description>Positive Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using Lithium Heparin tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
          <group group_id="O3">
            <title>Positive Predictive Value in Serum Separator</title>
            <description>Positive Predictive Value for the ARCHITECT High Sensitive Troponin I was evaluated using Serum tube type for 3 collection time points. The results were calculated using the overall 99th percentile cutoff (26.2 pg/mL).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Performance- Positive Predictive Value (PPV)</title>
          <description>The ARCHITECT STAT High Sensitive Troponin-I assay clinical performance was evaluated by calculating the Positive Predictive Value. The ARCHITECT STAT High Sensitive Troponin-I assay results were generated from subject's specimens collected at three collection time points in three tube types (K2 EDTA, Lithium Heparin Separator and Serum Separator).</description>
          <population>The number of subjects for analysis was determined by the number of subjects with at least one collection time point in the respective tube type (K2 EDTA, Lithium Heparin Separator, Serum Separator). Not all time points or collection tube types were able to be collected for all subjects.</population>
          <units>%MI,TnI &gt;cutoff vs all TnI &gt; cutoff</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1066"/>
                <count group_id="O2" value="1088"/>
                <count group_id="O3" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% PPV: 0-2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.78" lower_limit="31.92" upper_limit="45.98"/>
                    <measurement group_id="O2" value="36.82" lower_limit="30.43" upper_limit="43.56"/>
                    <measurement group_id="O3" value="35.84" lower_limit="28.70" upper_limit="43.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% PPV: 2-4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.68" lower_limit="29.03" upper_limit="42.76"/>
                    <measurement group_id="O2" value="35.75" lower_limit="29.43" upper_limit="42.45"/>
                    <measurement group_id="O3" value="35.94" lower_limit="29.16" upper_limit="43.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% PPV: 4-9 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.49" lower_limit="29.99" upper_limit="43.38"/>
                    <measurement group_id="O2" value="37.75" lower_limit="31.71" upper_limit="44.09"/>
                    <measurement group_id="O3" value="35.05" lower_limit="28.36" upper_limit="42.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>38.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.92</ci_lower_limit>
            <ci_upper_limit>45.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>35.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.03</ci_lower_limit>
            <ci_upper_limit>42.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>36.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.99</ci_lower_limit>
            <ci_upper_limit>43.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>36.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.43</ci_lower_limit>
            <ci_upper_limit>43.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>35.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.43</ci_lower_limit>
            <ci_upper_limit>42.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>37.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.71</ci_lower_limit>
            <ci_upper_limit>44.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 0-2 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>35.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.70</ci_lower_limit>
            <ci_upper_limit>43.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 2-4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>35.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.16</ci_lower_limit>
            <ci_upper_limit>43.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Time point: 4-9 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Positive Predictive Value</param_type>
            <param_value>35.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>28.36</ci_lower_limit>
            <ci_upper_limit>42.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of subject emergency department visit: 24 hours.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ARCHITECT STAT High Sensitive Troponin I Assay Testing</title>
          <description>All subjects will have their blood tested by the investigational Troponin I assay.
ARCHITECT STAT High Sensitive Troponin I Assay: Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay.
Results obtained will be used to assess the prognosis of subjects with a troponin result for risk of ACM/MACE in the time frames (30 days and 90 days) after the Emergency Department visit.
Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Some tube types and some time points may not have been obtained for each subject. Every attempt was made to collect all tube types within the time point windows described.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Karla Grasso, Clinical Research Manager</name_or_title>
      <organization>Abbott Diagnostics Division</organization>
      <phone>1 224-667-5602</phone>
      <email>karla.grasso@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

